在心力衰竭中的免疫代谢
Ioanna Andreadou1, Alessandra Ghigo2, Panagiota-Efstathia Nikolaou1
1Laboratory of Pharmacology, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Nature reviews. Cardiology
|June 21, 2025
概括
心力衰竭涉及炎症和新陈代谢 (免疫代谢) 之间的复杂相互作用. 了解这些途径是开发新疗法的关键,这些疗法可以促进愈合并改善患者的治疗结果.
科学领域:
- 心血管医学 心血管医学
- 免疫学 免疫学 免疫学
- 代谢科学 代谢科学
背景情况:
- 炎症和新陈代谢 (免疫新陈代谢) 是心力衰竭病理生理学的核心,无论其来源 (缺血或代谢障碍) 或排泄分数.
- 心肌中免疫细胞的透和极化是由代谢变化驱动的,影响心脏和全身代谢.
- 这种免疫代谢交叉作用有助于不良的心脏重塑和慢性炎症,延续心力衰竭的进展.
研究的目的:
- 为了解决心力衰竭中控制免疫代谢的细胞和分子机制提供全面的概述.
- 讨论针对心力衰竭中的免疫代谢的当前和潜在的治疗策略.
- 探索心力衰竭患者的非侵入性监测和治疗方法.
主要方法:
- 对心力衰竭中免疫代谢现有文献的综述.
- 对参与免疫细胞透和代谢转变的细胞和分子通路的分析.
- 讨论药理和免疫调节干预措施.
主要成果:
- 确定免疫细胞和心脏细胞之间的双向代谢交叉,有助于不利的重塑.
- 突出了新陈代谢转变在免疫细胞两极分化中的作用 (促炎与抗炎).
- 强调了由损伤和代谢失调驱动的骨髓形成的慢性炎症的延续.
结论:
- 了解免疫代谢对于开发新的心力衰竭疗法至关重要.
- 针对代谢途径和免疫反应,有可能改善患者的治疗结果.
- 需要进一步的研究来克服免疫调节方法的挑战,并制定有效的监测策略.
相关概念视频
Pathophysiology of Heart Failure
1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Heart Failure II: Pathophysiology
33
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
33
Heart Failure I: Introduction
49
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
49
Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21


